The rationale behind this study is that patients with mismatch-repair-proficient, BRAF V600E-mutant, high-risk, stage II or III colon cancer face a significant risk of recurrence, despite receiving standard adjuvant therapy. Here, BRAF is linked to malignant colon neoplasm.